The adult therapeutic substitution protocol follows:
|
|
- Allen Reed
- 5 years ago
- Views:
Transcription
1 Therapeutic Substitution of Albuterol - Implemented 1/15/2013 After years of evaluation, comparative studies have not consistently demonstrated clinical or safety advantages of levalbuterol over racemic albuterol. Both drugs have similar effects on heart rate when comparable doses are used (similar increases among both tachycardic and non-tachycardic patient groups). No difference in the length of inpatient hospital stay has been identified. No differences in the Emergency Department treatment requirements have been seen, nor have differences been demonstrated in the length of ER visits. The cost of levalbuterol is prohibitive compared to albuterol. Medical City spent over $200,000 on levalbuterol in The same number of treatments could have been performed using albuterol at a cost of $15,000. After consideration of efficacy, safety, and cost, the Pharmacy & Therapeutics Committee has approved the therapeutic substitution of albuterol for levalbuterol orders in adults. Pediatric physicians are encouraged to utilize albuterol and it will be promoted by pediatric hospital staff members. The adult therapeutic substitution protocol follows: Drug Prescribed Xopenex 0.63mg Q8h Xopenex 1.25mg Q8h Xopenex 0.63mg Q2, Q4, or Q6h Xopenex 1.25mg Q2, Q4, or Q6h Drug Dispensed/Administered Albuterol 1.25mg Q6h Albuterol 2.5mg Q6h Albuterol 1.25mg at same frequency Albuterol 2.5mg at same frequency For an adult patient who has been found to be intolerant to albuterol, the physician may obtain levalbuterol by indicating Do not substitute as part of the order. Page 1
2 Medical City Hospital Therapeutic Interchange proposal: Levalbuterol (Xopenex) to Racemic Albuterol Background: Levalbuterol (Xopenex) is a β-2 agonist indicated for treatment and prevention of bronchospasm. Levalbuterol is the R-enantiomer of albuterol (e.g., Proventil), a 50:50 mixture of R-albuterol and S-albuterol. Levalbuterol (R-albuterol) causes bronchodilation, while in vitro S-albuterol increases airway hyperreactivity and is pro-inflammatory. Early evidence implied that levalbuterol, at a dose one-fourth that of racemic albuterol, could produce equivalent bronchodilation with fewer side effects. Thus, a product containing only the R-enantiomer alone (i.e., Xopenex) should be more effective and cause fewer side effects. However, both levalbuterol and racemic albuterol present similar dose-related adverse effect profiles. Common adverse reactions include deterioration of asthma, β-adrenergic side effects (tachycardia, tremor, nervousness), hypokalemia and hyperglycemia. The incidence of asthma and increase/change in glucose and potassium levels is comparable in levalbuterol and racemic albuterol. Numerous studies have compared levalbuterol to albuterol for asthma in various settings: adults, pediatrics, ICU, emergency room, etc. Clinical Trials: In the study by Nelson, the change in peak FEV1 response to the first dose in the combined levalbuterol group was significantly greater compared with the combined racemic albuterol group (0.92 and 0.82 L, respectively; P =.03), with similar but non-significant results after 4 weeks (0.84 and 0.74 L, respectively). The greatest increase in FEV1 was seen after levalbuterol 1.25 mg, especially in subjects with severe asthma. Author concluded that levalbuterol appears to provide a better therapeutic index than the standard dose of racemic albuterol. In a study by Kelly using a double-blind, parallel-group design in 328 asthma patients, patients were randomly assigned to levalbuterol 0.63mg or 1.25mg, R,S-albuterol 1.25mg or 2.5mg, or placebo. The drug was administered by nebulization three times a day for four weeks. Improvement in peak FEV1 after four weeks was similar in the combined levalbuterol vs combined albuterol groups (p=0.13). Heart rate increased 3.6 beats/min with levalbuterol 1.25mg and 4.9 beats/min with albuterol 2.5mg. The percentage of patients reporting tremor or nervousness did not differ between the levalbuterol 0.63 mg and albuterol 2.5 mg groups (p=0.098). Other comparative studies in chronic asthma have not shown differences between levalbuterol and albuterol in regard to FEV1. In a study in the emergency department setting published by Nowak, 627 adults with severe asthma were randomized to levalbuterol 1.25mg or albuterol 2.5mg. Medications were given by nebulization every 20 minutes times three, then every 40 minutes times three, then as needed for 24 hours. All patients also received prednisone. The primary outcome measure was time to discharge. Secondary outcomes were FEV1 improvement and need for admission. Levalbuterol improved FEV1 slightly more than albuterol (p=0.02). However, improvement Page 2
3 was not sustained and did not shorten ED length of stay. There was no difference in time to discharge or need for hospitalization. However, hospitalization rate was lower with levalbuterol in a subset of patients not using inhaled corticosteroids at home (3.8% vs 9.3%, p=0.03). In the ICU setting, the effects of 2.5 mg albuterol and levalbuterol 1.25 mg on heart rate were compared in the study by Lam. The mean increase in heart rate was about 2 beats per minute in the patients with tachycardia. Heart rate increased by a mean of about 4 beats per minute in patients without baseline tachycardia. There was no significant difference between albuterol and levalbuterol. Study by Quereshi in the emergency department setting enrolled 129 children ages 2-14 with moderate to severe asthma. Patients were randomized to levalbuterol 2.5mg or albuterol 5mg. Medications were given by nebulization every 20 minutes times three, then every 30 to 60 minutes as needed. All children received prednisone. Primary outcome measures were changes from baseline in asthma score and FEV1 after the first, third, and fifth treatments. Secondary outcomes included need for hospitalization, heart rate, length of emergency department stay, number of treatments, and oxygen saturation. There were no significant differences between groups in primary or secondary outcomes or adverse effects. The study was underpowered to detect a difference in FEV1. Another study by Carl JC for pediatric asthma patients presenting to an emergency department for acute asthma were randomized to levalbuterol 1.25 mg or albuterol 2.5 mg. The primary outcome measures were need for hospitalization and speed of improvement. Fewer patients in the levalbuterol group required hospitalization (36% vs 45%; p=0.02). Although the study reported a lower hospital admission rate compared to albuterol, their baseline admission rate was higher than other reports. Use of two or more albuterol treatments before presentation was associated with increased risk of admission (RR 1.39, p=0.002) although length of hospital stay was similar in both groups. Mean heart rate and mean maximal heart rate were similar between the levalbuterol and albuterol groups. The investigators did not see a difference in tremor between groups. Recently in 2011, Khorfan et al compared albuterol to levalbuterol using a randomized, singleblind, crossover, prospective study in 70 critically ill adult patients. Patients were randomized to alternating nebulized combination of albuterol or levalbuterol with ipratropium every 4 to 6 hours. Group A received albuterol 2.5mg alternating with levalbuterol 0.63 mg. Group B received albuterol 2.5 mg alternating with levalbuterol 1.25 mg. Heart rate was recorded before and after each treatment. In group A, change in heart rate after albuterol was 0.89 ± 4.5 beats/min (n= 303) compared with 0.85 ± 5.3 beats/min after levalbuterol (n= 301, P=.89). In group B, heart rate decreased 0.16 _ 5.1 beats/min after albuterol 2.5 mg (n= 114) compared to an increase of 1.4 ± 5.4 beats/min after levalbuterol 1.25 mg (n= 118, P=.03). Authors concluded that nebulized albuterol and ipratropium does not cause significant tachycardia or tachyarrhythmias. Substitution of levalbuterol for albuterol to avoid tachycardia and tachyarrhythmias is unwarranted. Page 3
4 Conclusions from clinical trials: Older trials suggested an advantage for levalbuterol over racemic albuterol. However, most data suggesting such benefit were retrospective and non-randomized trials. The newer trials have failed to confirm these advantages. Comparative studies have not shown the clinical advantages of levalbuterol over racemic albuterol. For most patients, there was no difference in hospital length of stay or need for hospitalization. Both drugs have similar effects on heart rate when comparable doses are used, and there's no proof that albuterol causes more inflammation and agitation. It is possible that certain subsets of patients might achieve greater bronchodilation from levalbuterol than albuterol. This includes patients requiring high doses of albuterol. Also, hospitalization rate was lower with levalbuterol in a subset of patients not using inhaled corticosteroids at home. Prospective study in such subsets is needed. There may be a greater increase in FEV1 after first dose of levalbuterol vs albuterol. However, initial improvement in FEV1 has not lead to decreased length of stay or treatment requirements in the ED. Current data do not support routine use of levalbuterol over albuterol. For most patients, albuterol is just as effective, safe and well-tolerated as levalbuterol. The National Asthma Education and Prevention Program (NAEPP) guidelines state that levalbuterol, at half the dose of albuterol, produces similar bronchodilation and side effects as albuterol [Evidence level A; High-quality randomized controlled trial (RCT)]. Dose Equivalency: Based on a study by Lotvall and colleagues, as well as the AUC and C max data provided in the Xopenex product labeling, the bronchoprotective effects and plasma concentrations of 1.25mg of Xopenex is closest to a dose of 2.5mg of racemic albuterol. Dose Equivalency Chart Xopenex (levalbuterol) 1.25mg 0.63mg Albuterol (racemic) 2.5mg 1.25mg Page 4
5 Proposal for therapeutic interchange of levalbuterol (Xopenex) to racemic albuterol: Prescribed* Xopenex 0.63mg Q8h Xopenex 1.25mg Q8h Xopenex 0.63mg Q2, Q4, or Q6h Xopenex 1.25mg Q2, Q4, or Q6h Profiled & Dispensed Albuterol 1.25mg Q6h Albuterol 2.5mg Q6h Albuterol 1.25mg at same frequency Albuterol 2.5mg at same frequency *The presence or absence of PRN status will not affect the interchange. Physicians may override the interchange by indicating Do not substitute or similar phrases in the chart. Comparative usage at MCD over last 12 months Albuterol usage at MCD (1.25mg/0.5ml) 853 units $4, Albuterol usage at MCD (2.5mg/3ml) 444 units $4, Total Albuterol (last 12 months) 1297 units $8, Xopenex usage at MCD (1.25mg/0.5ml): 2669 units $208, Drug Cost: Albuterol 1.25 mg / 3 ml - $4.77, $0.16/unit Levalbuterol (Xopenex) 1.25 mg / 0.5ml - $78.10, $2.60/unit References: 1. Kelly HW. Levalbuterol for asthma: a better treatment? Curr Allergy Asthma Rep 2007;7: National Asthma Education and Prevention Program, U.S. Department of Health and Human Services, National Institutes of Health, Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma: Full Report Nowak R, Emerman C, Hanrahan JP, et al. A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med 2006;24: Lam S, Chen J. Changes in heart rate associated with nebulized racemic albuterol and levalbuterol in intensive care patients. Am J Health Syst Pharm 2003;60: Berger WE, Milgrom H, Skoner DP, et al. Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a doubleblind, randomized, placebo- and active-controlled trial. Curr Med Res Opin 2006;22: Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr 2003;143: Qureshi F, Zaritsky A, Welch C, et al. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med 2005;46: Nelson HS, Bensch G, Pleskow WW, DiSantostefano R, DeGraw S, Reasner DS, Rollins TE, Rubin PD. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol Dec;102(6 Pt 1): Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. 9. Lotvall J, Palmquist M, Arvidsson P, Maloney A, Ventresca GP, Ward J. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001;108: Khorfan FM, Smith P, Watt S, Barber KR. Effects of nebulized bronchodilator therapy on heart rate and arrhythmias in critically ill adult patients. Chest 2011; 140; Page 5
Asthma is a leading cause of health-related disability and hospitalization for children, and the prevalence of asthma has
High-Dose Continuous Nebulized Levalbuterol for Pediatric Status Asthmaticus: A Randomized Trial Timothy Andrews, MD, Erin McGintee, MD, Manoj K. Mittal, MD, Lisa Tyler, RRT, Amber Chew, Xuemei Zhang,
More informationEvidence behind use of levosalbutamol over salbutamol to prevent cardiac side effects
International Journal of Contemporary Pediatrics Lahiri S. Int J Contemp Pediatr. 2017 May;4(3):674-678 http://www.ijpediatrics.com pissn 2349-3283 eissn 2349-3291 Review Article DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20171682
More informationEffects of Aerosolized Levosalbutamol Verses Salbutamol on Serum Potassium Level and Heart Rate in Children with Acute Exacerbation of Asthma
Original Article DOI: 10.17354/ijss/2016/90 Effects of Aerosolized Levo Verses Salbutamol on Serum Potassium Level and Heart Rate in Children with Acute Exacerbation of Asthma Sayid M Barkiya 1, Veena
More informationAsthma and COPD in the ICU
Asthma and COPD in the ICU Prescott Woodruff, MD, MPH Assistant Professor Medicine in Residence Pulmonary and Critical Care Medicine, Department of Medicine Acute Exacerbations of Asthma Asthma exacerbations
More informationImpact of levalbuterol versus Albuterol in Kentucky Medicaid Patients
University of Kentucky UKnowledge MPA/MPP Capstone Projects Martin School of Public Policy and Administration 2010 Impact of levalbuterol versus Albuterol in Kentucky Medicaid Patients Velma Henry University
More informationPHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 11/16/17 SECTION: DRUGS LAST REVIEW DATE: 11/16/17 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
LEVALBUTEROL HFA (levalbuterol tartrate) inhalation aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationPEDIATRIC ACUTE ASTHMA SCORE (P.A.A.S.) GUIDELINES. >97% 94% to 96% 91%-93% <90% Moderate to severe expiratory wheeze
Inclusion: Children experiencing acute asthma exacerbation 24 months to 18 years of age with a diagnosis of asthma Patients with a previous history of asthma (Consider differential diagnosis for infants
More informationSupplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus
Supplementary Medications during asthma attack Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Conflicts of Interest None Definition of Asthma Airway narrowing that is
More informationLow-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol
Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol Henry Milgrom, MD, a David P. Skoner, MD, b George Bensch, MD, c Kenneth T. Kim, MD,
More informationSCVMC RESPIRATORY CARE PROCEDURE
Page 1 of 8 Rev. - 11/99, 11/05, 4/11 R-NC - 08/99,08/00, 04/03,10/08,04/09, 07/11, 6/12 B7180-43 OBJECTIVE Continuous Nebulization allows for continuous, controlled drug delivery to the lung, avoiding
More informationNovember 2009 Based on DERP report Dated October 2008
Quick Relief Medicines For Asthma November 2009 Based on DERP report Dated October 2008 DRAFT Produced by: The Health Resources Commission Office for Oregon Health Policy & Research 1225 Ferry Street SE
More informationDOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
More information10/6/2014. Tommy s Story: An Overview of Asthma Mangement. Disclosure. Objectives for this talk.
Tommy s Story: An Overview of Asthma Mangement Clifton C. Lee, MD, FAAP, FHM Associate Professor of Pediatrics Chief, Pediatric Hospital Medicine Children s Hospital of Richmond at VCU Disclosure Obviously,
More informationThe Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
More informationAcute Asthma in the Emergency Room
Acute Asthma in the Emergency Room José A. Castro-Rodríguez, MD, PhD Escuela de Medicina Pontificia Universidad Católica de Chile Potential ConConflict of Interest: In the last three years, I received
More informationBUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
More informationI. Subject: Continuous Aerosolization of Bronchodilators
I. Subject: Continuous Aerosolization of Bronchodilators II. Indications: A. Acute airflow obstruction in which treatment with an aerosolized bronchodilator is desired for an extended period of time, i.e.
More informationManagement of Acute Asthma Exacerbations in Children 2012 Update. Sharon Kling Dept Paediatrics & Child Health University of Stellenbosch
Management of Acute Asthma Exacerbations in Children 2012 Update Sharon Kling Dept Paediatrics & Child Health University of Stellenbosch Acknowledgements BTS/SIGN guidelines GINA guidelines NAEPP guidelines
More informationRapid Effects of Inhaled Corticosteroids in Acute Asthma Gustavo J. Rodrigo, MD.
Rapid Effects of Inhaled Corticosteroids in Acute Asthma Gustavo J. Rodrigo, MD WWW.chestjournal.org Background: Current reviews on the use of inhaled corticosteroids (ICS) for acute asthma underestimated
More informationDrug Class Review. Quick-relief Medications for Asthma
Drug Class Review Quick-relief Medications for Asthma Final Update 1 Report Evidence Tables October 2008 The purpose of reports is to make available information regarding the comparative clinical effectiveness
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018
Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation
More informationKirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo,
Kirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo, BRONCHODILATORS: Beta Adrenoreceptor Agonists Actions Adrenoreceptor agonists have many of the same actions as epinephrine/adrenaline,
More informationPredicting, Preventing and Managing Asthma Exacerbations. Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa
Predicting, Preventing and Managing Asthma Exacerbations Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa Asthma exacerbations Predicting exacerbation recognising
More informationThe New England Journal of Medicine EFFECT OF NEBULIZED IPRATROPIUM ON THE HOSPITALIZATION RATES OF CHILDREN WITH ASTHMA. Subjects
EFFECT OF NEBULIZED IPRATROPIUM ON THE HOSPITALIZATION RATES OF CHILDREN WITH FAIQA QURESHI, M.D., JOHN PESTIAN, PH.D., PARIS DAVIS, B.A., AND ARNO ZARITSKY, M.D. ABSTRACT Background Anticholinergic medications
More informationMedications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources
Medications for Managing COPD in Hospice Patients Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Goal of medications in COPD Decrease symptoms and/or complications Reduce frequency
More informationOBSERVATION UNIT ASTHMA PATHWAY OUTLINE Westmoreland Hospital PAGE 1 OF 5
PAGE 1 OF 5 Exclusion Criteria: (Reason to admit to hospital) A. New EKG changes except sinus tachycardia B. Respiratory Rate > 40 C. Signs/symptoms of Heart Failure D. Impending respiratory failure or
More informationSample. Affix patient label within this box.
Instructions for completing orders Complete pages 1-3 for General Inpatient Orders. All pathway compatible orders (indicated by ) within the General Inpatient Orders will be followed automatically. Optional
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationAsthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
More informationChallenges in Meeting International Requirements for Clinical Bioequivalence of Inhaled Drug Products
Challenges in Meeting International Requirements for Clinical Bioequivalence of Inhaled Drug Products Tushar Shah, M.D. Sr. VP, Global Respiratory Research and Development TEVA Pharmaceuticals 1 Presentation
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationDrug Class Review on Quick-relief Medications for Asthma
Drug Class Review on Quick-relief Medications for Asthma Preliminary Scan Report #3 November 2013 The Agency for Healthcare Research and Quality has not yet seen or approved this report The purpose of
More informationSHORT COMMUNICATION. Abstract. Kevin R. Murphy, 1 Tom Uryniak, 2 Ubaldo J. Martin 2 and James Zangrilli 2
SHORT COMMUNICATION Drugs R D 212; 12 (1): 9-14 1179-691/12/1-9 ª 212 Murphy et al., publisher and licensee Adis Data Information BV. This is an open access article published under the terms of the Creative
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationTreatment of Acute Asthma Exacerbations in Adults in the Primary Care or Urgent Care Setting Clinical Practice Guideline MedStar Health.
Treatment of Acute Asthma Exacerbations in Adults in the Primary Care or Urgent Care Setting Clinical Practice Guideline MedStar Health Background: These guidelines are provided to assist physicians and
More informationPharmacokinetics, pharmacodynamics, and the delivery of pediatric bronchodilator therapy
Pharmacokinetics, pharmacodynamics, and the delivery of pediatric bronchodilator therapy David P. Skoner, MD Pittsburgh, Pa β 2 -adrenergic receptor agonists have long been used for the amelioration of
More informationDATE: 09 December 2009 CONTEXT AND POLICY ISSUES:
TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY
More informationObjectives. Case Presentation. Respiratory Emergencies
Respiratory Emergencies Objectives Describe how to assess airway and breathing, including interpreting information from the PAT and ABCDEs. Differentiate between respiratory distress, respiratory failure,
More information2/12/2015. ASTHMA & COPD The Yin &Yang. Asthma General Information. Asthma General Information
ASTHMA & COPD The Yin &Yang Arizona State Association of Physician Assistants March 6, 2015 Sedona, Arizona Randy D. Danielsen, PhD, PA-C, DFAAPA Dean & Professor A.T. Still University Asthma General Information
More informationSYNOPSIS. First subject enrolled 15 August 2003 Therapeutic confirmatory (III) Last subject completed 03 February 2005
Drug product: SYMBICORT pmdi 160/4.5 μg Drug substance(s): Budesonide/formoterol Study code: SD-039-0728 Edition No.: FINAL Date: 27 February 2006 SYNOPSIS A 52-week, randomized, double-blind, single-dummy,
More informationAsthma Coding Fact Sheet for Primary Care Pediatricians
01/01/2017 Asthma Coding Fact Sheet for Primary Care Pediatricians Physician Evaluation & Management Services Outpatient 99201 99202 99203 99204 99205 Office or other outpatient visit, new patient; self
More informationLONG-ACTING BETA AGONISTS
LONG-ACTING BETA AGONISTS AND ICS/LABA COMBINATIONS DISCLOSURE Dr. Francisco has no financial interest in any commercial entity discussed in this presentation Dr. Francisco will not discuss experimental
More informationFour of 10 patients with asthma suffer moderate REVIEW DUAL-CONTROLLER REGIMENS II: OBSERVATIONAL DATA. Michael S. Blaiss, MD ABSTRACT
DUAL-CONTROLLER REGIMENS II: OBSERVATIONAL DATA Michael S. Blaiss, MD ABSTRACT The differences between clinical trials and clinical practice often create difficulty for generalizing results of controlled
More informationIntegrating Evidence-Based Pediatric Prehospital Protocols into Practice EMSC Targeted Issues Grant #H34MC19347 ASK THE QUESTION Question 1:
Integrating Evidence-Based Pediatric Prehospital Protocols into Practice EMSC Targeted Issues Grant #H34MC19347 Children with Respiratory Distress Prehospital Protocol Evidence-Based Practice Summary ASK
More informationThe FDA Critical Path Initiative
The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary
More informationIs reslizumab effective in improving quality of life and asthma control in adolescent and adult patients with poorly controlled eosinophilic asthma?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Is reslizumab effective in improving
More informationINPATIENT ASTHMA CARE PROTOCOL
INPATIENT ASTHMA CARE PROTOCOL When ordered by a physician, an eligible child 2 years of age or older who is admitted to the General Pediatric Inpatient Unit at the Children s Hospital of Georgia with
More informationSYNOPSIS THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
Drug product: Drug substance(s): Document No.: Edition No.: 1 Study code: Accolate Zafirlukast (ZD9188) 9188IL/0138 Date: 02 May 2007 SYNOPSIS A Multicenter, Randomized, Double-blind, -controlled, Parallel
More informationEmily DiMango, MD Asthma II
Emily DiMango, MD Asthma II Director John Edsall/John Wood Asthma Center Columbia University Medical Center HP 2000 Goal: 2.25/1,000 Comparison of Asthma Hospitalization Rates in Children Aged 0-14 in
More informationLecture Notes. Chapter 3: Asthma
Lecture Notes Chapter 3: Asthma Objectives Define asthma and status asthmaticus List the potential causes of asthma attacks Describe the effect of asthma attacks on lung function List the clinical features
More informationEarly Studies. Then, the Meta-analysis. Recent Studies Al-Ansari. Recent Studies Luo University of Texas Health Science Center at San Antonio
Pediatrics Grand Rounds Objectives Review the available literature on the use of nebulized hypertonic saline in the treatment of acute viral bronchiolitis Review proposed mechanism(s) of action and safety
More informationPediatric Respiratory Disease: A Model for the Future of Emergency Medicine Research
Pediatric Respiratory Disease: A Model for the Future of Emergency Medicine Research Joseph J. Zorc, MD, MSCE Mark Fishman Professor, Department of Pediatrics Perelman School of Medicine, University of
More informationAsthma is global health problem in children,
Paediatrica Indonesiana VOLUME 52 July NUMBER 4 Original Article Efficacy of salbutamol-ipratropium bromide nebulization compared to salbutamol alone in children with mild to moderate asthma attacks Matahari
More informationTREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN. Dr Lại Lê Hưng Respiratory Department
TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN Dr Lại Lê Hưng Respiratory Department Literature review current through: Feb 2013. This topic last updated: Aug 14, 2012 INTRODUCTION Wheezing
More informationand the Concord Repatriation General Hospital, Concord, Sydney, NSW, Australia (LT). Copyright 2002 by Lippincott Williams & Wilkins
Pediatric Critical Care Randomized, double-blind, placebo-controlled trial of intravenous salbutamol and nebulized ipratropium bromide in early management of severe acute asthma in children presenting
More informationIs Oral Dexamethasone Safe and Effective for Treating Asthma Exacerbations In Pediatric Patients?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is Oral Dexamethasone Safe and Effective
More informationRelevant Papers: eight relevant articles were found, but four were reviewed because they were most directly related to the topic
Topic: Prehospital use of bromide paired with salbutamol as treatment for shortness of breath. Author: Lisa Henderson Clinical Scenario: Two primary care paramedics respond code 4 for a 55 year old male
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung
More informationAsthma Medications: Information for Children and Families. What You Need to Know about Medicines for Asthma
Page 1 of 8 PED-ALL-005-1992 Asthma Medications: Information for Children and Families What You Need to Know about Medicines for Asthma What Medicines Are used to Treat Asthma? There are two kinds of medicines:
More informationASTHMA IN THE PEDIATRIC POPULATION
ASTHMA IN THE PEDIATRIC POPULATION SEARCH Rotation 2 August 23, 2010 Objectives Define asthma as a chronic disease Discuss the morbidity of asthma in pediatrics Discuss a few things that a health center
More informationMN-221, a Novel Beta2-Adrenergic Agonist for Treatment of Acute Asthma and COPD
MN-221, a Novel Beta2-Adrenergic Agonist for Treatment of Acute Asthma and COPD Brian M. Sadler PhD, Alan Dunton MD, Ernest Kitt, James Bosley PhD, Ron Beaver PhD November 2010 MediciNova, Inc. Rosa &
More informationXOPENEX Inhalation Solution (levalbuterol hydrochloride)
DISCLAIMER All labeling reflected on this website is for informational and promotional purposes only. It is not intended to be used by healthcare professionals or patients for the purpose of prescribing
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationAT TRIAGE. Alberta Acute Childhood Asthma Pathway: Evidence based* recommendations For Emergency / Urgent Care
1 1 Should the child be placed into the Pathway? Asthma Clinical Score (PRAM) Inclusion Children 1 year and 18 years of age who present with wheezing and respiratory distress, and have been diagnosed by
More informationRobert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network
Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network Robert.kruklitis@lvh.com Correlation of a Asthma pathophyisology with basic science Asthma (Physiology) Bronchodilators
More informationSYNOPSIS. Date 15 June 2004
Drug product Drug substance(s) Document No. Edition No. Study code SYMBICORT pmdi 160/4.5 mg per actuation Budesonide/formoterol SD-039-0719 Date 15 June 2004 SYNOPSIS A Six-Month, Randomized, Open-Label
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationEmergency Department Protocol Initiative
Emergency Department Protocol Initiative ACUTE ASTHMA MANAGEMENT TOOLKIT March 2006 Provincial Emergency Services Project PHYSICIAN ORDER TEMPLATE FOR CTAS LEVEL 1 ASTHMA ADULT PEDIATRIC Date: Site: Arrival
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationEfficacy of Nebulised Ipratropium in Acute Bronchial Asthma
ORIGINAL ARTICLE JIACM 2002; 3(4): 353-59 Efficacy of Nebulised Ipratropium in Acute Bronchial Asthma Praveen Aggarwal*, Onkar Singh**, Jyoti P Wali***, Rohini Handa*, Sada N Dwivedi****, Ashutosh Biswas*****,
More informationMAYA RAMAGOPAL M.D. DIVISION OF PULMONOLOGY & CYSTIC FIBROSIS CENTER
MAYA RAMAGOPAL M.D. DIVISION OF PULMONOLOGY & CYSTIC FIBROSIS CENTER 16 year old female with h/o moderate persistent asthma presents to the ED after 6 hours of difficulty breathing, cough, and wheezing
More informationIt is recommended that a mask and protective eyewear be worn when providing care to a patient with a cough
UNIVERSITY HEALTH NETWORK POLICY #: PAGE 1 OF 7 POLICY AND PROCEDURE MANUAL: RESPIRATORY THERAPY DEPT PATIENT CARE SECTION ORIGINAL DATE: 04/03 ISSUED BY: SITE LEADER APPROVED BY: Infection Prevention
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications
More informationDespite many advances in the
Single-dose intravenous salbutamol bolus for managing children with acute severe asthma in the emergency department: Reanalysis of data* Gary J. Browne, FRACP, FACEM; Lawrence T. Lam, MApp, PsyMPH Objective:
More informationKey words: acute asthma treatment; albuterol; -agonists; intermittent or continuous nebulization
Continuous vs Intermittent -Agonists in the Treatment of Acute Adult Asthma* A Systematic Review With Meta-analysis Gustavo J. Rodrigo, MD; and Carlos Rodrigo, MD Background: Since the late 1980s, there
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects
More informationPatient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationADASUVE (LOXAPINE) INHALATION POWDER. EDUCATION PROGRAM for HEALTHCARE PROFESSIONALS
ADASUVE (LOXAPINE) INHALATION POWDER EDUCATION PROGRAM for HEALTHCARE PROFESSIONALS August2017 December 2012 PMR-JUN-2017-0017 ADASUVE Risk Evaluation and Mitigation Strategy (REMS) Education Program Content
More informationImproved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma
Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma Harold S. Nelson, MD, a George Bensch, MD, b Warren W. Pleskow, MD, c Rachael DiSantostefano, MS, d Sidney
More informationSHORT ACTING BETA 2 AGONISTS (SABA) Lisa Romard, RN, MSN, CPNP, ANP, AE-C
SHORT ACTING BETA 2 AGONISTS (SABA) Lisa Romard, RN, MSN, CPNP, ANP, AE-C Short-acting Beta 2-agonists medications Albuterol ( Albuterol nebulizer solution, Accuneb, Proventil HFA, Ventolin HFA, ProAir
More informationSOME STATISTICAL CONSIDERATIONS IN THE DESIGN AND ANALYSIS OF EQUIVALENCE STUDIES USING PHARMACODYNAMIC AND CLINICAL ENDPOINTS
SOME STATISTICAL CONSIDERATIONS IN THE DESIGN AND ANALYSIS OF EQUIVALENCE STUDIES USING PHARMACODYNAMIC AND CLINICAL ENDPOINTS Scott Haughie, M.Sc., Senior Director, Biostatistics IPAC-RS/UF Orlando Inhalation
More informationAsthma Care in the Emergency Department Clinical Practice Guideline
Asthma Care in the Emergency Department Clinical Practice Guideline Inclusion: 1) Children 2 years of age or older with a prior history of wheezing, and 2) Children less than 2 years of age with likely
More informationAsthma in the Athlete
Asthma in the Athlete Jorge E. Gomez, MD Associate Professor Texas Children s Hospital Baylor College of Medicine Assist Team Physician UH Understand how we diagnose asthma Objectives Be familiar with
More informationDisclosure. Case. Objectives. Case Continued. Inhalers. Asthma: A GINA Update to the NAEPP 2007 Guidelines 1/20/2015
Disclosure Asthma: A GINA Update to the NAEPP 2007 Guidelines Robert (RC) Hellinga, Pharm.D. PGY 1 Pharmacy Resident Wolfson Children s Hospital/Baptist Health I do not have a vested interest in or affiliation
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationThe role of intrinsic efficacy in determining response to a b 2 -agonist in acute severe asthma $
Respiratory Medicine (2007) 101, 1007 1014 The role of intrinsic efficacy in determining response to a b 2 -agonist in acute severe asthma $ Nicola A. Hanania a,, Robert H. Moore b, Janice L. Zimmerman
More informationFoundations of Pharmacology
Pharmacologic Management of Asthma Objectives: 1. Review the physiological basis for asthma therapy 2. Discuss the differences between SABA and LABA 3. Discuss the role of inhaled and oral systemic corticosteroids
More information+ Asthma and Athletics
+ Asthma and Athletics Shaylon Rettig, MD, MBA Champion Sports Medicine + Financial Disclosure Dr. Shaylon Rettig has no relevant financial relationships with commercial interests to disclose. + Asthma
More informationBRICANYL INJECTION. terbutaline sulfate PRODUCT INFORMATION
BRICANYL INJECTION terbutaline sulfate PRODUCT INFORMATION NAME OF THE MEDICINE Terbutaline sulfate, 2-(tert-butylamino)-1-(3,5-dihydroxyphenyl) ethanol sulfate, a sympathomimetic bronchodilator with a
More informationAcute Wheezing Emergencies: From Young to Old! Little Wheezers in the ED: Managing Acute Pediatric Asthma
Acute Wheezing Emergencies: From Young to Old! Little Wheezers in the ED: Managing Acute Pediatric Asthma Talk Outline Case Delivery of bronchodilators Meter-dose inhalers and spacers Continuous nebulization
More informationAsthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION
Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION Asthma Management in Pregnancy Effects of asthma on pregnancy outcomes Effects of pregnancy on asthma control Management
More informationUS max daily dose i Food and Drug Administration [2]
APPENDIX 2 etable 1. Regulatory limits on total daily dose for asthma medications Drugs Canadian max daily dose i Health Canada [1] US max daily dose i Food and Drug Administration [2] European max daily
More informationDiagnosis, Treatment and Management of Asthma
Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.
More informationManagement of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists Leonard B. Bacharier
Management of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists Leonard B. Bacharier Department of Pediatrics, Division of Allergy and Pulmonary Medicine, Washington
More informationQuick Literature Searches
Quick Literature Searches National Pediatric Nighttime Curriculum Written by Leticia Shanley, MD, FAAP Institution: University of Texas Southwestern Medical Center Case 1 It s 1:00am and you have just
More informationClinical trial efficacy: What does it really tell you?
Clinical trial efficacy: What does it really tell you? Joseph Spahn, MD Denver, Colo The primary goal of most clinical trials is an evaluation of the efficacy of the drug being evaluated. Therefore, it
More informationControversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies Stanley J. Szefler, MD Helen Wohlberg and Herman Lambert Chair in Pharmacokinetics, Head, Pediatric
More information